Isoray, Inc. ISR
We take great care to ensure that the data presented and summarized in this overview for Isoray, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ISR
Top Purchases
Top Sells
About ISR
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.
Insider Transactions at ISR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2024
|
Robert F Williamson Iii |
BUY
Open market or private purchase
|
Direct |
6,266
+0.73%
|
$18,798
$3.65 P/Share
|
|
Nov 25
2024
|
Jonathan Robert Hunt Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
12,829
+6.0%
|
$38,487
$3.74 P/Share
|
|
Nov 25
2024
|
Johan M. Spoor CEO |
BUY
Open market or private purchase
|
Indirect |
12,000
+29.51%
|
$36,000
$3.8 P/Share
|
|
Nov 25
2024
|
Johan M. Spoor CEO |
BUY
Open market or private purchase
|
Direct |
14,500
+8.7%
|
$43,500
$3.78 P/Share
|
|
Jun 17
2024
|
Jonathan Robert Hunt Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,800
+4.77%
|
$16,200
$9.81 P/Share
|
|
Jun 14
2024
|
Lori A Woods |
BUY
Open market or private purchase
|
Indirect |
4,587
+1.4%
|
$45,870
$10.85 P/Share
|
|
Jun 13
2024
|
Johan M. Spoor CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+42.09%
|
$100,000
$1.17 P/Share
|
|
Jun 03
2024
|
Lori A Woods |
BUY
Open market or private purchase
|
Indirect |
34,246
+2.16%
|
$34,246
$1.46 P/Share
|
|
May 31
2024
|
Jonathan Robert Hunt Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
25,006
+3.59%
|
$25,006
$1.4 P/Share
|
|
May 31
2024
|
Robert F Williamson Iii |
BUY
Open market or private purchase
|
Direct |
55,000
+11.49%
|
$55,000
$1.38 P/Share
|
|
May 29
2024
|
Robert F Williamson Iii |
BUY
Open market or private purchase
|
Direct |
30,031
+3.98%
|
$30,031
$1.33 P/Share
|
|
Apr 23
2024
|
Mark John Austin VP Finance/Prin Fin&Acct Offic |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+26.31%
|
$0
$0.36 P/Share
|
|
Mar 06
2024
|
Lantheus Alpha Therapy, LLC |
BUY
Open market or private purchase
|
Direct |
60,431,039
+34.1%
|
$0
$0.95 P/Share
|
|
Jan 30
2024
|
Robert F Williamson Iii |
BUY
Open market or private purchase
|
Direct |
127,206
+7.66%
|
$0
$0.71 P/Share
|
|
Jan 29
2024
|
Robert F Williamson Iii |
BUY
Open market or private purchase
|
Direct |
25,266
+5.6%
|
$0
$0.64 P/Share
|
|
Jan 26
2024
|
Robert F Williamson Iii |
BUY
Open market or private purchase
|
Direct |
110,613
+13.72%
|
$0
$0.58 P/Share
|
|
Jan 25
2024
|
Robert F Williamson Iii |
BUY
Open market or private purchase
|
Direct |
22,134
+22.63%
|
$0
$0.49 P/Share
|
|
Jan 24
2024
|
Markus Puhlmann Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
280,000
+16.91%
|
$0
$0.5 P/Share
|
|
Jan 24
2024
|
Robert F Williamson Iii |
BUY
Open market or private purchase
|
Direct |
29,862
+35.8%
|
$0
$0.49 P/Share
|
|
Dec 21
2023
|
Robert F Williamson Iii |
BUY
Open market or private purchase
|
Indirect |
3,663
+50.0%
|
$0
$0.33 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 62.3M shares |
|---|---|
| Exercise of conversion of derivative security | 30K shares |